// App-Quantinova.ai

: Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Researchers

Presenter

  • Filip Ionescu

Principal Investigators

  • Aamia Leach

  • Melissa Alsina

  • Nelli Bejanyan

  • Omar Castaneda-Puglianini

  • Hany Elmariah

  • Ciara L. Freeman

  • Doris K. Hansen

  • Michael D. Jain

  • Farhad Khimani

  • Aleksandr Lazaryan

  • Hien D. Liu

  • Frederick L. Locke

  • Bryan McIver

  • Asmita Mishra

  • Michael Nieder

  • Jose Ochoa

  • Lia Perez

  • Joseph Pidala

  • Aliyah Baluch

  • Olga Klinkova

  • Rod Quilitz

  • Taiga Nishihori

  • Rawan Faramand

Medical Centers

  • Endocrine Oncology, H. Lee Moffitt Cancer Center, Tampa, FL

  • Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H.Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • Department of Hematology and Oncology, H. Lee Moffitt Cancer Center/University of South Florida, Tampa, FL

  • Department of Bone Marrow Transplant Infectious Diseases, H. Lee Moffitt Cancer Center, tampa, FL

  • Bone Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

  • Infectious Diseases, Moffitt Cancer Center, Tampa, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Oncology (ONC)

Disease

  • Coronavirus disease

  • Solid malignancies

Biomarkers

  • Hematocrit

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved